Evogene to Present at the Jefferies Virtual Synthetic Biology Week on March 23, 2022
Evogene Ltd. (NASDAQ: EVGN) announced its participation in the Jefferies Virtual Synthetic Biology Week from March 21-25, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evogene Ltd. (NASDAQ: EVGN) announced its participation in the Jefferies Virtual Synthetic Biology Week from March 21-25, 2022. Chief Product Officer, Dr. Nir Arbel, will engage in a fireside chat on March 23, 2022, at 10 am ET and will be available for one-on-one meetings with investors on March 24, 2022. Evogene aims to transform life-science product development through its innovative technological engines: MicroBoost AI, ChemPass AI, and GeneRator AI. These engines focus on microbiome therapeutics, medical cannabis, ag-chemicals, and ag-biologicals.
Details
News Market Reaction – EVGN
The recorded move for EVGN in the trading session of this news was -4.07%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REHOVOT, Israel, March 14, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it will be attending the Jefferies Virtual Synthetic Biology Week which is taking place between March 21-25, 2022.
Evogene's Chief Product Officer, Dr. Nir Arbel, will participate in a fireside chat at 10am ET on Wednesday, March 23, 2022. Dr. Arbel, will also be available for one-on-one virtual meetings with investors on Thursday, March 24, 2022.
Investors that wish to meet with Dr. Arbel, are welcome to coordinate the meeting via their Jefferies representatives. Alternatively, investors may also contact Evogene's investor relations team which will coordinate a meeting.
About Evogene Ltd.:
Evogene (NASDAQ: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase probability of success while reducing development time and cost. Evogene established three unique technological engines - MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its technological engines to develop products through subsidiaries and with strategic partners. Currently, Evogene's main subsidiaries utilize the technological engines to develop human microbiome-based therapeutics by Biomica Ltd., medical cannabis products by Canonic Ltd., ag-chemicals by AgPlenus and ag-biologicals by Lavie Bio Ltd. For more information, please visit: www.evogene.com.
Investor Relations Contact:
|
Kenny Green GK Investor Relations E: evogene@gkir.com T: +1 212 378 8040
|
Logo - https://mma.prnewswire.com/media/890385/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-to-present-at-the-jefferies-virtual-synthetic-biology-week-on-march-23-2022-301501740.html
SOURCE Evogene
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.